Juelg | Ragon Institute of Mass General, MIT, and Harvard

Boris D. Juelg

Boris D. Juelg, MD, PhD

Principal Investigator

Group Leader

Ragon Institute of Mass General, MIT, and Harvard

Infectious Diseases Division

MGH

Center for Virology and Vaccine Research

BIDMC

Contact

857-268-7088

400 TS 754

Infectious Diseases Clinical Research Unit

Center for Virology and Vaccine Research

Natural infections informing immunotherapies

Research Overview

The Juelg lab aims to link preclinical and clinical studies to identify and test the most promising immunological strategies to prevent and treat infections. The lab is specifically interested in evaluating passive and active immunization approaches using broadly neutralizing antibodies and novel vaccine candidates.

About

Dr. Juelg received an MD and PhD from Christian Albrecht University in Kiel, Germany. He completed a postdoctoral research fellowship with Dr. Bruce Walker before undergoing internal medicine training at MGH and a fellowship in infectious diseases through the combined program at MGH and Brigham and Women’s Hospital.

Selected Publications

Learning from HIV-1 to predict the immunogenicity of T cell epitopes in SARS-COV-2

Ang Gao, Zhilin Chen, Assaf Amitai, Julia Doelger, Vamsee Mallajosyula, Emily Sundquist, Florencia Pereyra Segal, Mary Carrington, Mark M Davis, Hendrik Streeck, Arup K. Chakraborty, Boris Julg.

iScience. 2021

Viral rebound kinetics correlate with distinct HIV antibody features

Bartsch YC, Loos C, Rossignol E, Fajnzylber JM, Yuan D, Avihingsanon A, Ubolyam S, Jupimai T, Hirschel B, Ananworanich J, Lauffenburger DA, Li JZ, Alter G, Julg B.

mBio. 2021 Mar 9;12(2):e00170-21

Predicting the broadly neutralizing antibody susceptibility of the HIV reservoir

Yu WH, Su D, Torabi J, Fennessey CM, Shiakolas A, Lynch R, Chun TW, Doria-Rose N, Alter G, Seaman MS, Keele BF, Lauffenburger DA, Julg B.

JCI Insight. 2019 Sep 5;4(17)

Recommendations for Analytical Antiretroviral Treatment Interruptions in HIV Research Trials – Report of a Consensus Meeting

Julg B, Dee L, Ananworanich K, Barouch DH, Bar K, Caskey M etc al.

Lancet HIV, 2019 Apr;6(4):e259-e268

Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail.

Julg B, Liu PT, Wagh K, Fisher W, Abbink P, Mercado N, Whitney JB, Schmidt SD, Nkolola J, McMahan K, Borducchi E, Tartaglia LP, Seaman MS, Mascola JR, Burton DR, Korber B, Barouch DH.

2017, Sci Transl Med. 2017 Sep 20;9(408) pii: eaao4235

Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer robust protection against a clade C SHIV challenge

Julg B, Tartaglia LP, Keele B, Wagh K, Pegu A, Sok D, Abbink P, Schmidt SD, Wang K, Chen X, Joyce MG, Georgiev IS, Choe M, Kwong PD, Doria-Rose NA, Le K, Louder MK, Bailer RT, Moore PL, Korber B, Seaman MS, Abdool Karim SS, Morris L, Koup RA, Mascola JR, Burton DR, Barouch DH.

2017, Sci Transl Med. 2017 Sep 6;9(406)

A high-throughput single-cell analysis of human CD8+ T cell functions reveals discordance for cytokine secretion and cytolysis

Varadarajan N, Julg B, Yamanaka YJ, Chen H, Ogunniyi AO, McAndrew E, Porter LC, Piechocka-Trocha A, Hill BJ, Douek DC, Pereyra F, Walker BD, Love JC.

J Clin Invest. 2011 Nov 1;121(11):4322-31

Lab Team

Yannic Bartsch

Research Fellow

Ellie Burgess

Research Technician I

Hacheming Compere

Research Technician I